MBX — Microbix Biosystems Cashflow Statement
0.000.00%
- CA$35.58m
- CA$29.88m
- CA$25.39m
- 66
- 73
- 27
- 56
Annual cashflow statement for Microbix Biosystems, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.23 | 3.23 | 1.79 | -0.039 | 3.52 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 3.52 | 1.27 | 0.98 | -1.99 | 0.989 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.461 | -3.22 | -0.34 | -0.22 | -1.77 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 0.009 | 2.11 | 3.47 | -1.09 | 4.35 |
| Capital Expenditures | -0.814 | -1.24 | -2.03 | -1.02 | -1.91 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 0.621 | 0 | — | — |
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.814 | -0.622 | -2.03 | -1.02 | -1.91 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.802 | 8.41 | 2.06 | 0.229 | -1.08 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.003 | 9.89 | 3.5 | -1.88 | 1.36 |